CoChat

A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE)

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Rationale: This is the first multicenter randomized controlled trial to evaluate the effectiveness and safety of Zephyr Endobronchial Valve (EBV) in patients with little to no collateral ventilation out to 12 months. Objectives: To evaluate the effectiveness and safety of Zephyr EBV in heterogeneous emphysema with little to no collateral ventilation in the treated lobe. Methods: Subjects were enrolled with a 2:1 randomization (EBV/standard of care [SoC]) at 24 sites. Primary outcome at 12 months was the ΔEBV–SoC of subjects with a post-bronchodilator FEV1 improvement from baseline of greater than or equal to 15%. Secondary endpoints included absolute changes in post-bronchodilator FEV1, 6-minute-walk distance, and St. George’s Respiratory Questionnaire scores. Measurements and Main Results: A total of 190 subjects (128 EBV and 62 SoC) were randomized. At 12 months, 47.7% EBV and 16.8% SoC subjects had a ΔFEV1 greater than or equal to 15% (P < 0.001). ΔEBV–SoC at 12 months was statistically and clinically significant: for FEV1, 0.106 L (P < 0.001); 6-minute-walk distance, +39.31 m (P = 0.002); and St. George’s Respiratory Questionnaire, −7.05 points (P = 0.004). Significant ΔEBV–SoC were also observed in hyperinflation (residual volume, −522 ml; P < 0.001), modified Medical Research Council Dyspnea Scale (−0.8 points; P < 0.001), and the BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index (−1.2 points). Pneumothorax was the most common serious adverse event in the treatment period (procedure to 45 d), in 34/128 (26.6%) of EBV subjects. Four deaths occurred in the EBV group during this phase, and one each in the EBV and SoC groups between 46 days and 12 months. Conclusions: Zephyr EBV provides clinically meaningful benefits in lung function, exercise tolerance, dyspnea, and quality of life out to at least 12 months, with an acceptable safety profile in patients with little or no collateral ventilation in the target lobe. Clinical trial registered with www.clinicaltrials.gov (NCT 01796392).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201803-0590oc

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Criner, 2018, Effectiveness of the Zephyr® endobronchial valves (EBV®) in patients with severe emphysema: clinical outcomes from LIBERATE, a multicenter RCT [abstract], A7752

Cited by

See all 438

Metadata

Authors
Criner, G. J., Sue, R., Wright, S., Dransfield, M., Rivas-Perez, H., Wiese, T., Sciurba, F. C., Shah, P. L., Wahidi, M. M., de Oliveira, H. G., Morrissey, B., Cardoso, P. F. G., Hays, S., Majid, A., Pastis, N., Kopas, L., Vollenweider, M., McFadden, P. M., Machuzak, M., Hsia, D. W., Sung, A., Jarad, N., Kornaszewska, M., Hazelrigg, S., Krishna, G., Armstrong, B., Shargill, N. S., & Slebos, D.-J.
Affiliations
  • Temple University (US)
  • St. Joseph's Hospital and Medical Center (US)
  • University of Alabama at Birmingham (US)
  • University of Louisville (US)
  • University of Pittsburgh (US)
  • Royal Brompton Hospital (GB)
  • Duke University (US)
  • Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
  • University of California, Davis (US)
  • Universidade de São Paulo (BR)
  • University of California, San Francisco (US)
  • Beth Israel Deaconess Medical Center (US)
  • Medical University of South Carolina (US)
  • Houston Methodist (US)
  • Orlando Health (US)
  • University of Southern California (US)
  • Cleveland Clinic (US)
  • University of California, Los Angeles (US)
  • Stanford Health Care (US)
  • University Hospitals Bristol NHS Foundation Trust (GB)
  • University Hospital of Wales (GB)
  • SIU Medicine (US)
  • Palo Alto Medical Foundation (US)
  • QST Consultations Ltd., Allendale, Michigan
  • Pulmonx (United States) (US)
  • University Medical Center Groningen (NL)
Corresponding author
Criner, Gerard J.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2018-11-01
Volume
198
Issue
9
Pages
1151-1164
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2785216066
Cited by
428
References
40
Citations by year
2026: 41 · 2025: 49 · 2024: 80 · 2023: 57 · 2022: 40 · 2021: 44 · 2020: 50 · 2019: 50 · 2018: 16
FWCI
30.14
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by-nc)
  • TUScholarShare (Temple University) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Funders
Pulmonx Corporation
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords
endobronchial valves, heterogeneous emphysema, collateral ventilation, FEV1 improvement, 6-minute walk distance, St George's Respiratory Questionnaire, hyperinflation, dyspnea, BODE index, pneumothorax, lung volume reduction, chronic obstructive pulmonary disease, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). https://app.cochat.ai/papers/10.1164/rccm.201803-0590oc
The paper
Criner, G. J., Sue, R., Wright, S., Dransfield, M., Rivas-Perez, H., Wiese, T., Sciurba, F. C., Shah, P. L., Wahidi, M. M., de Oliveira, H. G., Morrissey, B., Cardoso, P. F. G., Hays, S., Majid, A., Pastis, N., Kopas, L., Vollenweider, M., McFadden, P. M., Machuzak, M., . . . Slebos, D.-J. (2018). A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201803-0590oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.